CHJ.20505
Lysostaphin from Staphylococcus staphylolyticus
--
--
Ordering
Available Variants5 mg
CHJ.20505-5mg
Price
€371.20
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHJ.20505-5mg | €371.20 |
Suitable for manufacturing of diagnostic kits and reagents., lyophilized powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| CAS Number | 9011-93-2 |
|---|---|
| UNSPSC Code | 12352204 |
| NACRES | NA.32 |
| EC Number | 3.4.24.75 (BRENDA, IUBMB) |
| MDL number | MFCD00131556 |
| Specific activity | ≥500 units/mg protein |
| Biological source | bacterial (Staphylococcus sp.) |
| Concentration | 50—70% protein |
Safety Information Handling visibility
| pictograms |
GHS08
GHS08
|
|---|---|
| signalword | Danger |
| hcodes | H334 |
| pcodes | P261 - P284 - P501 |
| Hazard Classifications | Resp. Sens. 1 |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Lysostaphin, a glycylglycine endopeptidase, is an enzyme derived from Staphylococcus staphylolyticus with the CAS number 9011-93-2. This enzyme exhibits a unique ability to cleave the pentaglycine crosslinks in the peptidoglycan layer of bacterial cell walls, specifically targeting Staphylococcus species. The mechanism of action of lysostaphin involves the hydrolysis of these crosslinks, ultimately leading to the lysis of bacterial cells. As a result, lysostaphin has been explored as a potential therapeutic agent for the treatment of Staphylococcus-related infections, particularly those caused by methicillin-resistant Staphylococcus aureus. The enzymes specificity and efficacy against these bacteria make it an attractive candidate for further research and development as an antimicrobial agent, offering a potential alternative to traditional antibiotics. Further studies are necessary to fully elucidate the potential of lysostaphin as a therapeutic agent.
